Amgen (AMGN) Change in Cash (2009 - 2026)
Amgen (AMGN) posted Change in Cash of $2.0 billion for Q2 2026, down 32.93% on a QoQ basis from $2.9 billion in Q1 2026, and up 349.49% year-over-year from $434.0 million in Q2 2025.
Analysis
Amgen (AMGN) Change in Cash (2009 - 2026) Analysis & Trends
Amgen has reported Change in Cash for 18 years, with the latest figure at $2.0 billion in Q2 2026.
- On a quarterly basis, Change in Cash rose 349.49% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $6.0 billion, a 568.26% increase from a year earlier, with the FY2025 full-year figure at -$2.8 billion, down 376.38% from the prior year.
- Change in Cash was $2.0 billion for Q2 2026 at Amgen, down from $2.9 billion in the prior quarter.
- The five-year high for Change in Cash was $23.9 billion in Q1 2023, with the low at -$23.8 billion in Q4 2023.
- Average Change in Cash over 5 years is $333.3 million, with a median of -$303.0 million recorded in 2024.
- The largest YoY upside for Change in Cash was 1737.99% in 2023 against a maximum downside of 1170.53% in 2023.
- Over 5 years, Change in Cash stood at -$1.9 billion in 2022, then slumped by 1170.53% to -$23.8 billion in 2023, then soared by 112.45% to $3.0 billion in 2024, then slumped by 110.67% to -$316.0 million in 2025, then soared by 717.41% to $2.0 billion in 2026.
- The last three Change in Cash figures came in at $2.0 billion (Q2 2026), $2.9 billion (Q1 2026), and -$316.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -4.45 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 649.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -504.60 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -185.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -170.44 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | -37.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Bn |
| Mar 31, 2026 | 2.91 Bn |
| Dec 31, 2025 | -316.00 Mn |
| Sep 30, 2025 | 1.42 Bn |
| Jun 30, 2025 | -782.00 Mn |
| Mar 31, 2025 | -3.16 Bn |
| Dec 31, 2024 | 2.96 Bn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | -407.00 Mn |
| Mar 31, 2024 | -1.24 Bn |
| Dec 31, 2023 | -23.80 Bn |
| Sep 30, 2023 | 493.00 Mn |
| Jun 30, 2023 | 2.69 Bn |
| Mar 31, 2023 | 23.93 Bn |
| Dec 31, 2022 | -1.87 Bn |
| Sep 30, 2022 | 4.30 Bn |
| Jun 30, 2022 | -1.33 Bn |
| Mar 31, 2022 | -1.46 Bn |
| Dec 31, 2021 | -3.98 Bn |
| Sep 30, 2021 | 5.34 Bn |